148 related articles for article (PubMed ID: 38444861)
21. Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial.
Yardley DA; Brufsky A; Coleman RE; Conte PF; Cortes J; Glück S; Nabholtz JM; O'Shaughnessy J; Beck RM; Ko A; Renschler MF; Barton D; Harbeck N
Trials; 2015 Dec; 16():575. PubMed ID: 26673577
[TBL] [Abstract][Full Text] [Related]
22. A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma.
Sarivalasis A; Boudousquié C; Balint K; Stevenson BJ; Gannon PO; Iancu EM; Rossier L; Martin Lluesma S; Mathevet P; Sempoux C; Coukos G; Dafni U; Harari A; Bassani-Sternberg M; Kandalaft LE
J Transl Med; 2019 Nov; 17(1):391. PubMed ID: 31771601
[TBL] [Abstract][Full Text] [Related]
23. Randomized phase II study comparing docetaxel plus cisplatin, docetaxel plus carboplatin, and paclitaxel plus carboplatin in patients with advanced or recurrent endometrial carcinoma: a Japanese Gynecologic Oncology Group study (JGOG2041).
Nomura H; Aoki D; Takahashi F; Katsumata N; Watanabe Y; Konishi I; Jobo T; Hatae M; Hiura M; Yaegashi N
Ann Oncol; 2011 Mar; 22(3):636-642. PubMed ID: 20696677
[TBL] [Abstract][Full Text] [Related]
24. Phase II Trial of Neoadjuvant Carboplatin and Nab-Paclitaxel in Patients with Triple-Negative Breast Cancer.
Yuan Y; Lee JS; Yost SE; Li SM; Frankel PH; Ruel C; Schmolze D; Robinson K; Tang A; Martinez N; Stewart D; Waisman J; Kruper L; Jones V; Menicucci A; Uygun S; Yoder E; van der Baan B; Yim JH; Yeon C; Somlo G; Mortimer J
Oncologist; 2021 Mar; 26(3):e382-e393. PubMed ID: 33098195
[TBL] [Abstract][Full Text] [Related]
25. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
26. A randomized controlled phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy of newly diagnosed glioblastoma (GlioVax): study protocol for a randomized controlled trial.
Rapp M; Grauer OM; Kamp M; Sevens N; Zotz N; Sabel M; Sorg RV
Trials; 2018 May; 19(1):293. PubMed ID: 29801515
[TBL] [Abstract][Full Text] [Related]
27. A phase I/II study of bortezomib in combination with paclitaxel, carboplatin, and concurrent thoracic radiation therapy for non-small-cell lung cancer: North Central Cancer Treatment Group (NCCTG)-N0321.
Zhao Y; Foster NR; Meyers JP; Thomas SP; Northfelt DW; Rowland KM; Mattar BI; Johnson DB; Molina JR; Mandrekar SJ; Schild SE; Bearden JD; Aubry MC; Adjei AA
J Thorac Oncol; 2015 Jan; 10(1):172-80. PubMed ID: 25247339
[TBL] [Abstract][Full Text] [Related]
28. Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma.
Saberian C; Amaria RN; Najjar AM; Radvanyi LG; Haymaker CL; Forget MA; Bassett RL; Faria SC; Glitza IC; Alvarez E; Parshottam S; Prieto V; Lizée G; Wong MK; McQuade JL; Diab A; Yee C; Tawbi HA; Patel S; Shpall EJ; Davies MA; Hwu P; Bernatchez C
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34021033
[TBL] [Abstract][Full Text] [Related]
29. Feasibility study of paclitaxel plus carboplatin in patients with endometrial cancer: a Japan Kanto Tumor Board study (JKTB trial).
Yamada K; Tanabe H; Imai M; Jobo T; Kudo K; Fujiwara H; Nagata C; Furuya K; Suzuki M; Ochiai K; Tanaka T; Yasuda M
J Obstet Gynaecol Res; 2013 Jan; 39(1):311-6. PubMed ID: 22639962
[TBL] [Abstract][Full Text] [Related]
30. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
Loibl S; O'Shaughnessy J; Untch M; Sikov WM; Rugo HS; McKee MD; Huober J; Golshan M; von Minckwitz G; Maag D; Sullivan D; Wolmark N; McIntyre K; Ponce Lorenzo JJ; Metzger Filho O; Rastogi P; Symmans WF; Liu X; Geyer CE
Lancet Oncol; 2018 Apr; 19(4):497-509. PubMed ID: 29501363
[TBL] [Abstract][Full Text] [Related]
31. The Efficacy of Low-Dose Paclitaxel Added to Combination Chemotherapy of Carboplatin and Gemcitabine or Pegylated Liposomal Doxorubicin.
Nagao S; Iwasa N; Kurosaki A; Nishikawa T; Hanaoka T; Hasegawa K; Fujiwara K
Int J Gynecol Cancer; 2016 Mar; 26(3):443-8. PubMed ID: 26807640
[TBL] [Abstract][Full Text] [Related]
32. Autologous dendritic cells pulsed with allogeneic tumour cell lysate induce tumour-reactive T-cell responses in patients with pancreatic cancer: A phase I study.
Lau SP; Klaase L; Vink M; Dumas J; Bezemer K; van Krimpen A; van der Breggen R; Wismans LV; Doukas M; de Koning W; Stubbs AP; Mustafa DAM; Vroman H; Stadhouders R; Nunes JB; Stingl C; de Miranda NFCC; Luider TM; van der Burg SH; Aerts JG; van Eijck CHJ
Eur J Cancer; 2022 Jul; 169():20-31. PubMed ID: 35490565
[TBL] [Abstract][Full Text] [Related]
33. TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial.
Quoix E; Lena H; Losonczy G; Forget F; Chouaid C; Papai Z; Gervais R; Ottensmeier C; Szczesna A; Kazarnowicz A; Beck JT; Westeel V; Felip E; Debieuvre D; Madroszyk A; Adam J; Lacoste G; Tavernaro A; Bastien B; Halluard C; Palanché T; Limacher JM
Lancet Oncol; 2016 Feb; 17(2):212-223. PubMed ID: 26727163
[TBL] [Abstract][Full Text] [Related]
34. Phase II trial of combination nab-paclitaxel, carboplatin and gemcitabine in first line therapy of advanced urothelial carcinoma.
Alva A; Daignault S; Smith DC; Hussain M
Invest New Drugs; 2014 Feb; 32(1):188-94. PubMed ID: 24318901
[TBL] [Abstract][Full Text] [Related]
35. A phase II, open-labeled, single-arm study of dose-dense paclitaxel plus carboplatin in advanced or recurrent uterine endometrial cancer treatment: a KCOG-G1303, DOENCA trial.
Hori K; Nishio S; Ushijima K; Kasamatsu Y; Kondo E; Takehara K; Ito K
J Gynecol Oncol; 2021 Jul; 32(4):e64. PubMed ID: 34085798
[TBL] [Abstract][Full Text] [Related]
36. Phase II study of carboplatin in patients with advanced or recurrent endometrial carcinoma. A trial of the EORTC Gynaecological Cancer Group.
van Wijk FH; Lhommé C; Bolis G; Scotto di Palumbo V; Tumolo S; Nooij M; de Oliveira CF; Vermorken JB;
Eur J Cancer; 2003 Jan; 39(1):78-85. PubMed ID: 12504662
[TBL] [Abstract][Full Text] [Related]
37. Autologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: a prospective, randomized phase 2 trial.
Boudewijns S; Bloemendal M; de Haas N; Westdorp H; Bol KF; Schreibelt G; Aarntzen EHJG; Lesterhuis WJ; Gorris MAJ; Croockewit A; van der Woude LL; van Rossum MM; Welzen M; de Goede A; Hato SV; van der Graaf WTA; Punt CJA; Koornstra RHT; Gerritsen WR; Figdor CG; de Vries IJM
Cancer Immunol Immunother; 2020 Mar; 69(3):477-488. PubMed ID: 31980913
[TBL] [Abstract][Full Text] [Related]
38. Immunotherapy of autologous tumor lysate-loaded dendritic cell vaccines by a closed-flow electroporation system for solid tumors.
Kamigaki T; Kaneko T; Naitoh K; Takahara M; Kondo T; Ibe H; Matsuda E; Maekawa R; Goto S
Anticancer Res; 2013 Jul; 33(7):2971-6. PubMed ID: 23780988
[TBL] [Abstract][Full Text] [Related]
39. A phase I open-label study of selinexor with paclitaxel and carboplatin in patients with advanced ovarian or endometrial cancers.
Rubinstein MM; Grisham RN; Cadoo K; Kyi C; Tew WP; Friedman CF; O'Cearbhaill RE; Zamarin D; Zhou Q; Iasonos A; Nikolovski I; Xu H; Soldan KN; Caird I; Martin M; Guillen J; Eid KT; Aghajanian C; Makker V
Gynecol Oncol; 2021 Jan; 160(1):71-76. PubMed ID: 33139041
[TBL] [Abstract][Full Text] [Related]
40. A feasibility study of postoperative adjuvant therapy of carboplatin and weekly paclitaxel for completely resected non-small cell lung cancer.
Yamashita Y; Kataoka K; Ishida T; Matsuura M; Seno N; Mukaida H; Miyahara E; Miyata Y; Okita R; Shimizu K; Watari M; Okumichi T; Okada M
J Thorac Oncol; 2008 Jun; 3(6):612-6. PubMed ID: 18520800
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]